DE69840510D1 - Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung - Google Patents

Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung

Info

Publication number
DE69840510D1
DE69840510D1 DE69840510T DE69840510T DE69840510D1 DE 69840510 D1 DE69840510 D1 DE 69840510D1 DE 69840510 T DE69840510 T DE 69840510T DE 69840510 T DE69840510 T DE 69840510T DE 69840510 D1 DE69840510 D1 DE 69840510D1
Authority
DE
Germany
Prior art keywords
effect
ppar
cholesterol
delta
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840510T
Other languages
English (en)
Inventor
Teruhiko Shimokawa
Satomi Nishijima
Koyo Matsuda
Yuichi Iizumi
Seiichi Hashimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16387713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69840510(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DE69840510D1 publication Critical patent/DE69840510D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
DE69840510T 1997-07-24 1998-07-22 Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung Expired - Lifetime DE69840510D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19823297 1997-07-24
PCT/JP1998/003266 WO1999004815A1 (fr) 1997-07-24 1998-07-22 Compositions medicinales hypocholesterolemiantes

Publications (1)

Publication Number Publication Date
DE69840510D1 true DE69840510D1 (de) 2009-03-12

Family

ID=16387713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840510T Expired - Lifetime DE69840510D1 (de) 1997-07-24 1998-07-22 Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung

Country Status (9)

Country Link
US (1) US6300364B1 (de)
EP (1) EP1023907B1 (de)
JP (1) JP4427825B2 (de)
AT (1) ATE421336T1 (de)
AU (1) AU8355998A (de)
CA (1) CA2295930C (de)
DE (1) DE69840510D1 (de)
ES (1) ES2320181T3 (de)
WO (1) WO1999004815A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029876A1 (es) 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
AU1303301A (en) * 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
JP4256166B2 (ja) 2001-03-28 2009-04-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 カルボン酸化合物
US7244861B2 (en) 2001-03-30 2007-07-17 Eisai Co., Ltd. Benzene compound and salt thereof
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
US20040077689A1 (en) * 2001-04-25 2004-04-22 Yasuo Sugiyama Abc expression promoters
JPWO2002098840A1 (ja) 2001-06-04 2004-09-16 エーザイ株式会社 カルボン酸誘導体及びその塩もしくはそのエステルからなる医薬
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
JP4870464B2 (ja) * 2001-07-17 2012-02-08 帝人株式会社 ＰＰＡＲδ活性化作用を測定することを特徴とする物質の選択方法及び薬剤
US7396642B2 (en) * 2001-07-17 2008-07-08 Teijin Limited Methods of screening for a compound that enhances thermogenesis
CN1330641C (zh) * 2001-08-10 2007-08-08 日本化学医药株式会社 过氧化物酶体增殖剂响应受体δ活化剂
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
KR20040063897A (ko) 2001-09-14 2004-07-14 툴라릭, 인코포레이티드 링크된 바이아릴 화합물
MXPA04003398A (es) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
CN1688540A (zh) 2002-09-05 2005-10-26 诺沃挪第克公司 新颖的乙烯基羧酸衍生物以及它们的治疗用途
US7129268B2 (en) 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
AU2003273784A1 (en) 2002-10-28 2004-05-13 Novo Nordisk A/S Novel compounds useful in treating ppar mediated diseases
PL376718A1 (pl) 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki, ich wytwarzanie i stosowanie
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
SI1667964T1 (sl) 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
EP1745014B1 (de) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Neue verbindungen, deren herstellung und verwendung
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CN1997633A (zh) 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
US8111617B2 (en) * 2004-08-13 2012-02-07 Broadcom Corporation Multiple independent pathway communications
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JP2008533206A (ja) 2005-03-21 2008-08-21 メタボレックス インコーポレーティッド 代謝、炎症、および心血管障害の処置における浮腫を回避するための方法
BRPI0612730A2 (pt) 2005-06-30 2010-11-30 Novo Nordisk As compostos, suas preparações e uso
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2631390C (en) 2005-12-22 2014-03-11 Per Sauerberg Phenoxy acetic acids as ppar delta activators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
CN102643248A (zh) * 2006-04-18 2012-08-22 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
ES2399147T3 (es) 2006-09-08 2013-03-26 Rhode Island Hospital Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
EP2155769B1 (de) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Schutz gegen gewebedegeneration
CN104672220B (zh) * 2008-04-15 2017-09-22 日本化学医药株式会社 过氧化物酶体增殖剂活化受体的活化剂
EP2464349A2 (de) * 2009-08-14 2012-06-20 Cerenis Therapeutics S.A. Verwendung von ppar-delta-liganden für die behandlung oder prävention von entzündungen oder energiestoffwechsel-/produktionsbedingten erkrankungen
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3756661A1 (de) 2013-09-09 2020-12-30 vTv Therapeutics LLC Verwendung eines ppar-delta-agonisten zur behandlung von muskelatrophie
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858493B (en) * 1984-11-12 1986-07-30 Yamanouchi Pharma Co Ltd Heterocyclic compounds and process of producing them
JPS61268657A (ja) * 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
JPH0788426B2 (ja) 1986-07-30 1995-09-27 住友ベークライト株式会社 耐熱性樹脂の製造方法
JPH02215717A (ja) 1989-02-14 1990-08-28 Yamanouchi Pharmaceut Co Ltd 血清脂質低下剤
CZ281130B6 (cs) 1993-06-18 1996-06-12 Galena, A.S. Deriváty 4-alkyloxy-3-propyl-2-hydroxyacetofenonu
CA2194169A1 (en) 1994-07-01 1996-01-18 Ronald M. Evans Mammalian peroxisome proliferator-activated receptors and uses thereof
GB2292885A (en) 1994-09-08 1996-03-13 Merck & Co Inc Method of treating hyperlipidemia
WO1997010813A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
AU725998B2 (en) 1995-09-18 2000-10-26 Eisai R&D Management Co., Ltd. Treating NIDDM with RXR agonists
ES2241036T3 (es) 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents

Also Published As

Publication number Publication date
AU8355998A (en) 1999-02-16
US6300364B1 (en) 2001-10-09
CA2295930C (en) 2010-12-14
CA2295930A1 (en) 1999-02-04
EP1023907A4 (de) 2001-02-21
JP4427825B2 (ja) 2010-03-10
EP1023907B1 (de) 2009-01-21
WO1999004815A1 (fr) 1999-02-04
ATE421336T1 (de) 2009-02-15
ES2320181T3 (es) 2009-05-19
EP1023907A1 (de) 2000-08-02

Similar Documents

Publication Publication Date Title
DE69840510D1 (de) Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE69110561T2 (de) Mittel zur Behandlung und Vorbeugung von Bauchentzündungen, die als Wirkstoff Zink-L-Carnosin-Salze oder -Komplexe enthalten.
NO307336B1 (no) 2-[(Dihydro)pyrazolyl-3'-oksylmetylen]anilider, anvendelse derav, samt middel inneholdende forbindelsen og mellomprodukter for fremstilling av forbindelsen
DE59204094D1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien.
DK0468012T3 (da) 17beta-substituerede 4-aza-5alfa-androstan-3-on-derivater og fremgangsmåde til fremstilling deraf
ATE504573T1 (de) Pyrazolderivate, deren zwischenprodukte, verfahren zu deren herstellung und herbizid, das diese verbindungen als wirkstoff enthält
DE59108530D1 (de) Antimikrobielle Mittel sowie substituierte 2-Cyclohexan-1-yl-amin-Derivate und deren Herstellung
ATE147725T1 (de) Biguanidederivate, verfahren zu ihrer herstellung und diese enthaltende desinfektionsmittel
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
CY1108110T1 (el) Παραγοντες και μεθοδοι για προστασια, θεραπεια και επιδιορθωση συνδετικου ιστου
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
ATE213387T1 (de) N-arylhydrazinderivate als insektizide und akarizide mittel
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
ATE128459T1 (de) Sulfonanilidderivat und arzneimittel.
RU96101167A (ru) Брассиностероидное производное и его использование в качестве регулятора роста растений
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DK0674515T3 (da) Anvendelse af carbostyrilderivater til fremstilling af et medikament til inhibering af interleukin-8
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
ATE274904T1 (de) 4,5-dihydroxy-2-cyclopenten-1-on für die behandlung von diabetes mellitus
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
AU5759499A (en) Pparalpha and ppargamma inhibitors
DE69504272T2 (de) N-Arylthiohydrazon-Derivate als insektizide und akarazide Mittel
FI923662A (fi) Terapeutiska medel
ATE142200T1 (de) N-aminoalkylcarbonyloxyalkyl pyrrol enthaltende insekticide, acaricide und molluskizide mittel

Legal Events

Date Code Title Description
8363 Opposition against the patent